EsoCap’s vision is to improve the lives of patients with serious illnesses through the development of a unique topical drug delivery platform for diseases of the upper gastrointestinal tract. The EsoCap drug delivery platform will represent a CHANGE IN PARADIGM, similar as it happened with aerosol therapy in asthma. APPLICATION At the moment there are major limitations in the local treatment of diseases of the upper gastrointestinal tract. Our unique and smart application technology in the upper gastrointestinal tract is broadly applicable with established and novel drug substances. It will be beneficial in at least 6 indications affecting 370 Mio patients. COLLABORATION EsoCap is developing this novel platform together with major partners: the University of Greifswald in Germany with its institute, the C_DAT (Center of Drug Absorption and Transport), which is a leading European center of excellence operating since 2011. CLINICAL FEASIBILITY Our approach is to show the clinical feasibility for our unique drug delivery technology in one indication and to seek for a major partner within the biopharmaceutical industry. FIRST INDICATION The first indication will be eosinophilic esophagitis(EoE), a rare inflammatory disease of the esophagus. Current therapeutic options are limited to extremely strict dietary measures, off-label steroid treatment and one product registered only in the EU. These treatment options remain suboptimal for a vast majority of affected patients. EsoCap AG is led by one of the most experienced teams in the industry. Our team has founded, led and grown some of the most important companies impacting patients’ lives through the development and the commercialization of major life-transforming medicines.